Yisheng Pharmaceutical (002566.SZ) received a notice from the Jilin Provincial Medical Products Administration on the lifting of risk control measures.

Zhitong Finance APP News, Yisheng Pharmaceutical (002566.SZ) issued an announcement that on July 1, 2026, the company received the "Notice of Taking Risk Control Measures" (Ji Yao Cai Kong [2026] No. T02) issued by the Jilin Provincial Medical Products Administration. After receiving the notice, the company attached great importance to it and immediately established a special rectification working group, organizing the management and relevant business departments to compare the issues listed in the notice, sort them out item by item, deeply investigate the root causes of the problems, formulate a special rectification plan, and clarify the rectification tasks, responsible entities, and rectification deadlines. The company strictly advanced all rectification work in accordance with regulatory requirements, implemented rectification item by item for existing deficiencies, improved management systems, strengthened personnel training, and shored up internal control weaknesses. Today, the company received the "Notice of Lifting Risk Control Measures" (Ji Yao Jie Kong [2026] No. T02) issued by the Jilin Provincial Medical Products Administration. After on-site inspection and confirmation, potential safety hazards have been eliminated, and it is agreed to lift the risk control measures.